Hopkins Janet Jill 4

What Happened

• Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences (AURA), received awards on 2026-03-02 totaling 250,000 shares: 89,056 restricted stock units (RSUs) and 160,944 derivative/option-based units. Both grants were reported at $0.00 per share (no cash paid on grant).

Key Details

• Transaction date(s): 2026-03-02; filing date: 2026-03-03 (Form 4) — appears timely.
• Price: $0.00 per share for both awards (standard for compensation grants).
• Grant breakdown: 89,056 RSUs; 160,944 derivative/option-based shares — total 250,000.
• Vesting (footnotes):
  • RSUs (89,056): vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service.
  • Option-based shares (160,944): 25% vest on February 1, 2027; remaining 75% vests pro rata over the following 36 months, subject to continued service.
• Shares owned after transaction: not disclosed in the provided details.
• Transaction code: A = Award/Grant (compensation), not an open-market purchase or sale.

Context

• These awards are compensation grants intended as long-term incentives and do not represent an immediate market purchase or sale. The option-based award must vest before any exercise; nothing in this filing indicates exercise or sale of shares. Compensation grants are common for executives and should be viewed as part of pay/retention programs rather than a direct endorsement to buy or sell stock.